Surmodics INC Schedule 13G passive stakes

Trium Capital LLP has fully divested its entire stake in Surmodics Inc, reducing its beneficial ownership to zero percent.

Soleus Capital and its affiliates have reported a complete divestment of their beneficial ownership in Surmodics, Inc., reducing their stake to 0% as of September 30, 2025.

Trium Capital LLP has disclosed a 5.0% beneficial ownership stake in Surmodics Inc., holding 716,783 shares of common stock for investment purposes.

AllianceBernstein L.P. has disclosed a 5.9% beneficial ownership stake in Surmodics Inc., holding 849,354 common shares for investment purposes.

Barclays PLC has filed an amended Schedule 13G, indicating its beneficial ownership of Surmodics Inc. common stock remains at 5% or less, held in the ordinary course of business.

Barclays PLC has filed an amended Schedule 13G, disclosing a beneficial ownership of 7.26% of Surmodics Inc's common stock, totaling 1,039,058 shares as of December 31, 2024.

Ramya Rao, a UK-based individual, has disclosed a passive beneficial ownership of 7.26% of Surmodics Inc.'s common stock as of December 31, 2024.

Beryl Capital Management LLC and its affiliated entities, along with David A. Witkin, have filed an amendment to their Schedule 13G, indicating their beneficial ownership in Surmodics Inc. common stock has fallen below the 5% threshold.

Soleus Capital Master Fund, L.P. and its affiliated entities, including Guy Levy, have reported a collective beneficial ownership of 5.2% of Surmodics, Inc.'s common stock as of January 21, 2025.